Koenigsmann, M. and Casper, J. and Kahl, C. and Basara, N. and Sayer, H. G. and Behre, G. and Theurich, S. and Christopeit, M. and Mohren, M. and Reichle, A. and Metzner, B. and Ganser, A. and Stadler, M. and Uharek, L. and Balleisen, L. and Hinke, A. and Hinke, R. and Niederwieser, D. (2014) Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. BONE MARROW TRANSPLANTATION, 49 (3). pp. 410-415. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
Since the outcome of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP, patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (> 1 year after first CR who achieved CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory disease, 32% early and 32% late relapse. During DHAP treatment, progression occurred in 32% of patients. Of 33 patients who received TEC, 5 received second TEC and 15 allogeneic transplantation. Main toxicity after TEC was oral mucositis (CTC grades 3 and 4 in 50% and 13%, respectively). In total, 42% patients achieved CR. Median OS was 21.4 months for all patients and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative at predicting OS (P < 0.0001). Risk-adapted, treosulfan-based therapy with auto -and allo-SCT is feasible. Long-term survival is possible with allogeneic transplantation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; REDUCED-INTENSITY; SALVAGE THERAPY; BLOOD; MALIGNANCIES; FLUDARABINE; RITUXIMAB; relapsed non-Hogkin's lymphoma; treosulfan; autologous transplantation; allogeneic transplantation; risk-adapted; therapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Nov 2019 15:14 |
| Last Modified: | 19 Nov 2019 15:14 |
| URI: | https://pred.uni-regensburg.de/id/eprint/10574 |
Actions (login required)
 |
View Item |
